



Viatis Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

November 6, 2025

- Delivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business
- Makes Late-Stage Pipeline Progress Including NDA Submission for Low-Dose Estrogen Weekly Patch
- Acquires Aculyx Pharma Including Rights to Pitolisant in Japan and Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
- Returns More Than \$920 Million of Capital to Shareholders Year-to-Date, Including \$500 Million in Share Repurchases
- Raises and Narrows 2025 Financial Guidance Ranges for Total Revenues, Adjusted EBITDA and Adjusted EPS[1]

PITTSBURGH, Nov. 6, 2025 /PRNewswire/ -- [Viatis Inc.](#) (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial guidance.



Executive Commentary

"We delivered another strong quarter by staying focused on our 2025 strategic priorities," said [Scott A. Smith](#), Chief Executive Officer, Viatis. "Our performance this quarter reflects the continued strength of our execution across markets. We are advancing our pipeline with key regulatory submissions and preparing for multiple potential launches, while preparing to take meaningful actions through our enterprise-wide strategic review to position Viatis for sustainable growth in 2026 and beyond. We remain confident in our strategy, our people, and our ability to deliver significant impact for patients and long-term value for shareholders."

"Our third-quarter results again demonstrate strong operational execution and disciplined and balanced capital allocation," said [Doretta Mistras](#), Chief Financial Officer, Viatis. "We have returned more than \$920 million of capital to shareholders year-to-date, including \$500 million in share repurchases. We are raising and narrowing our financial guidance ranges across certain metrics primarily driven by foreign exchange and share repurchases, and we remain on track to deliver on all of our 2025 financial commitments."

[1] Viatis is not providing forward-looking guidance for U.S. GAAP net (loss) earnings or U.S. GAAP diluted EPS or a quantitative reconciliation of its 2025 adjusted EBITDA or adjusted EPS guidance. U.S. GAAP net cash provided by operating activities for 2025 is estimated to be between \$2.2 billion and \$2.45 billion, with a midpoint of approximately \$2.325 billion. 2025 financial guidance ranges as provided on November 6, 2025, exclude the impact of any transaction-related costs (as defined below), and acquired IPR&D for unsigned deals as they cannot be reasonably forecasted. See "2025 Financial Guidance" and "Non-GAAP Financial Measures" for additional information.

Third Quarter Results

	Three Months Ended September 30,				
	2025	2024	Reported Change	Operational Change ^{(1) (2)}	Divestiture Adjusted Operational Change ⁽¹⁾⁽²⁾
<i>(Unaudited; in millions, except %s and per share amounts)</i>					
Total Revenues	\$ 3,759.9	\$ 3,751.2	— %	(2) %	(1) %
Total Net Sales	\$ 3,747.5	\$ 3,738.0	— %	(2) %	(1) %

Developed Markets	2,255.6	2,298.7	(2) %	(5) %	(5) %
Emerging Markets	570.4	533.2	7 %	7 %	7 %
JANZ	306.3	344.3	(11) %	(10) %	(9) %
Greater China	615.2	561.8	10 %	9 %	9 %
Net Sales by Product Category					
Brands	\$ 2,436.8	\$ 2,362.2	3 %	1 %	1 %
Generics	1,310.7	1,375.8	(5) %	(6) %	(6) %
U.S. GAAP Gross Profit	\$ 1,371.5	\$ 1,459.2	(6) %		
U.S. GAAP Gross Margin	36.5 %	38.9 %			
Adjusted Gross Profit ⁽²⁾	\$ 2,104.4	\$ 2,192.9	(4) %		
Adjusted Gross Margin ⁽²⁾	56.0 %	58.5 %			
U.S. GAAP Net (Loss) Earnings	\$ (128.2)	\$ 94.8	NM		
U.S. GAAP (Loss) Earnings Per Share	\$ (0.11)	\$ 0.08	NM		
Adjusted Net Earnings ⁽²⁾	\$ 784.3	\$ 897.6	(13) %		
Adjusted EPS ⁽²⁾	\$ 0.67	\$ 0.75	(11) %	(10) %	(9) %
EBITDA ⁽²⁾	\$ 800.2	\$ 905.8	(12) %		
Adjusted EBITDA ⁽²⁾	\$ 1,154.6	\$ 1,284.6	(10) %	(10) %	(8) %
U.S. GAAP Net Cash Provided by Operating Activities	\$ 744.9	\$ 826.5	(10) %		
Capital Expenditures	86.8	77.0	13 %		
Free Cash Flow ⁽²⁾⁽³⁾	\$ 658.1	\$ 749.5	(12) %		

(1) See "Certain Key Terms and Presentation Matters" in this release for more information.

(2) Non-GAAP financial measures. See "Non-GAAP Financial Measures" for additional information.

(3) Excluding the impact of transaction-related costs of \$70 million, free cash flow for the three months ended September 30, 2025, was \$728 million. Excluding the impact of transaction-related costs of \$116 million, free cash flow for the three months ended September 30, 2024, was \$866 million.

	Nine Months Ended September 30,				
	2025	2024	Reported Change	Operational Change ^{(1) (2)}	Divestiture Adjusted Operational Change ⁽¹⁾⁽²⁾
<i>(Unaudited; in millions, except %s and per share amounts)</i>					
Total Revenues	\$ 10,596.3	\$ 11,211.2	(5) %	(6) %	(2) %
Total Net Sales	\$ 10,559.7	\$ 11,177.4	(6) %	(6) %	(2) %
Developed Markets	6,266.6	6,783.3	(8) %	(9) %	(4) %
Emerging Markets	1,645.4	1,737.7	(5) %	(4) %	1 %
JANZ	888.1	1,011.7	(12) %	(11) %	(9) %
Greater China	1,759.6	1,644.7	7 %	8 %	8 %
Net Sales by Product Category					
Brands	\$ 6,838.2	\$ 7,034.4	(3) %	(3) %	2 %
Generics	3,721.5	4,143.0	(10) %	(11) %	(8) %
U.S. GAAP Gross Profit	\$ 3,865.6	\$ 4,408.6	(12) %		
U.S. GAAP Gross Margin	36.5 %	39.3 %			
Adjusted Gross Profit ⁽²⁾	\$ 5,952.4	\$ 6,551.6	(9) %		
Adjusted Gross Margin ⁽²⁾	56.2 %	58.4 %			
U.S. GAAP Net Loss ⁽³⁾	\$ (3,174.8)	\$ (117.7)	NM		
U.S. GAAP Loss Per Share ⁽³⁾	\$ (2.70)	\$ (0.10)	NM		
Adjusted Net Earnings ⁽²⁾	\$ 2,110.6	\$ 2,536.8	(17) %		

Adjusted EPS ⁽²⁾	\$ 1.78	\$ 2.11	(16) %	(15) %	(9) %
EBITDA ⁽²⁾	\$ (938.8)	\$ 2,480.1	NM		
Adjusted EBITDA ⁽²⁾	\$ 3,156.9	\$ 3,685.9	(14) %	(14) %	(8) %
U.S. GAAP Net Cash Provided by Operating Activities	\$ 1,500.1	\$ 1,820.2	(18) %		
Capital Expenditures	182.3	185.6	(2) %		
Free Cash Flow ⁽²⁾⁽⁴⁾	\$ 1,317.8	\$ 1,634.6	(19) %		

(1) See "Certain Key Terms and Presentation Matters" in this release for more information.

(2) Non-GAAP financial measures. See "Non-GAAP Financial Measures" for additional information.

(3) For the nine months ended September 30, 2025, includes the previously disclosed goodwill impairment charge of \$2.9 billion as a result of the interim goodwill impairment test performed as of March 31, 2025.

(4) Excluding the impact of transaction-related costs of \$186 million, free cash flow for the nine months ended September 30, 2025, was \$1.5 billion. Excluding the impact of transaction-related costs of \$306 million, free cash flow for the nine months ended September 30, 2024, was \$1.9 billion.

Quarterly Financial Highlights

- Third quarter 2025 total revenues were \$3.8 billion, flat on a reported basis and down 1% on a divestiture-adjusted operational basis compared to third quarter 2024, primarily driven by the negative Indore Impact. Excluding the Indore Impact, divestiture-adjusted operational total revenues increased 1% compared to third quarter 2024.
- Brands net sales demonstrated continued strength in Greater China and Emerging Markets, in addition to growth in certain key brands in Developed Markets.
- Generics net sales reflect the expected negative Indore Impact, partially offset by growth in certain complex products in North America, strong performance across key European markets, and solid growth in Emerging Markets.
- The Company generated approximately \$100 million in new product revenues in the quarter.
- Third quarter 2025 U.S. GAAP net loss was \$(128) million compared to U.S. GAAP net earnings of \$95 million in the third quarter of 2024, and U.S. GAAP diluted EPS was \$(0.11) per share in Q3 2025 compared to \$0.08 per share in Q3 2024. The loss in the current quarter was primarily driven by a reduction in the fair value of the Company's investment in the compulsory convertible preferred shares of Biocon Biologics and an increase in income tax expense.
- Third quarter 2025 adjusted EBITDA was \$1.2 billion, down 10% on a reported basis and down 8% on a divestiture-adjusted operational basis compared to the third quarter of 2024, and adjusted EPS was \$0.67 per share in Q3 2025, down 11% on a reported basis and down 9% on a divestiture-adjusted operational basis compared to Q3 2024, in each case primarily driven by the negative Indore Impact.
- In the quarter, the Company generated U.S. GAAP net cash provided by operating activities of \$745 million and free cash flow of \$658 million, including \$70 million in transaction-related costs.

Additional Highlights

Brands

- **Acquisition of Aculy's Pharma, Inc.:** The Company announced the [completion of its acquisition of Aculy's Pharma, Inc.](#), a clinical biopharmaceutical company in Japan. As part of the transaction, Viartis has acquired exclusive development and commercialization rights in Japan for pitolisant, a selective/inverse agonist of the histamine H3 receptor. Based on the strength of recent Phase 3 clinical trial results in Japanese patients and the positive benefit-risk profile established globally, the Company is on track to file two JNDAs for pitolisant in Japan for two indications in the fourth quarter of 2025. One indication is for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy and the second is for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea syndrome. The transaction also includes exclusive rights in Japan and certain other markets in the Asia-Pacific region for Spydia® Nasal Spray, which was approved in Japan in June 2025 for the treatment of status epilepticus.

- **Low-Dose Estrogen Weekly Patch:** The New Drug Application for the Company's low-dose estrogen weekly patch was submitted to the U.S. Food and Drug Administration (FDA) in late Q3. The Company anticipates approval by mid-2026.

Generics

- **Iron Sucrose Injection:** The Company announced that the [FDA approved its Iron Sucrose Injection, USP](#), an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients (2 years of age and older) with chronic kidney disease. The product was made available in single dose vials in the following strengths: 50 mg/2.5mL, 100mg/5mL and 200mg/10mL.

Capital Allocation

Year-to-date, the Company has returned more than \$920 million of capital to shareholders, including \$500 million in share repurchases. The Company remains on track to deliver on its commitment of returning more than \$1 billion of capital to shareholders through dividends and share repurchases in 2025.

From a business development perspective, the Company continues to pursue targeted, accretive business development opportunities that leverage its unique commercial and R&D infrastructure and strengthen its business in key markets.

Enterprise-wide Strategic Review

Viatis has made significant progress on its enterprise-wide strategic review since it announced the initiative in February and continues to perform a detailed analysis of the totality of its business. As part of the analysis to date, the Company has identified areas for potential operating efficiencies, including from:

- its commercial sales and marketing model and product mix;
- its R&D, medical and regulatory activities;
- its sourcing, manufacturing and supply chain, including inventory optimization; and
- how its corporate functions provide support.

While the review is still ongoing, the Company anticipates being able to deliver meaningful net cost savings over a multi-year period while also being able to reinvest a portion of the savings back into the business to fund growth opportunities.

Investor Event

Viatis plans to hold an Investor Event in the first quarter of 2026 at which the Company plans to provide a strategic and financial outlook, an update on its pipeline and portfolio and details on its enterprise-wide strategic review.

2025 Financial Guidance

Viatis is updating its 2025 financial guidance ranges, as set forth below. The Company is not providing forward-looking guidance for U.S. GAAP net (loss) earnings or U.S. GAAP diluted (loss) earnings per share (EPS) or a quantitative reconciliation of its 2025 adjusted EBITDA or adjusted EPS guidance to the most directly comparable U.S. GAAP measures, U.S. GAAP net (loss) earnings or U.S. GAAP diluted EPS, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, future share repurchases, and other contingencies, such as changes to contingent consideration, acquired IPR&D and certain other gains or losses, including for the fair value accounting for non-marketable equity investments, as well as related income tax accounting, because certain of these items have not occurred, are out of the Company's control, and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period. With respect to the Estimated Ranges provided on November 6, 2025, U.S. GAAP net cash provided by operating activities for 2025 is estimated to be between \$2.2 billion and \$2.45 billion, with a midpoint of approximately \$2.325 billion. With respect to the Estimated Ranges provided on August 7, 2025, U.S. GAAP net cash provided by operating activities for 2025 was estimated to be between \$2.2 billion and \$2.5 billion, with a midpoint of approximately \$2.35 billion. With respect to the Estimated Ranges provided on August 7, 2025, Viatis did not provide forward-looking guidance for U.S. GAAP net (loss) earnings or U.S. GAAP diluted EPS or a quantitative reconciliation of its 2025 adjusted EBITDA or adjusted EPS guidance. Please see "Non-GAAP Financial Measures" for additional information.

<i>(In millions, except Adjusted EPS)</i>	Estimated Ranges ⁽²⁾ August 7, 2025	Midpoint ⁽²⁾ August 7, 2025	Acquired IPR&D	Share Repurchases ⁽³⁾	YTD FX Impact	Estimated Ranges ⁽⁴⁾ November 6, 2025	Midpoint ⁽⁴⁾ November 6, 2025
Total Revenues	\$13,500 - \$14,000	\$13,750	—	—	~\$350	\$13,900 - \$14,300	\$14,100
Adjusted EBITDA ⁽¹⁾	\$3,890 - \$4,190	\$4,040	(\$35)	—	~\$100	\$4,000 - \$4,200	\$4,100
Adjusted EPS ⁽¹⁾	\$2.16 - \$2.30	\$2.23	(\$0.03)	\$0.01	~\$0.07	\$2.25 - \$2.35	\$2.30
Free Cash Flow ⁽¹⁾	\$1,800 - \$2,200	\$2,000	—	—	N/A	\$1,850 - \$2,150	\$2,000

(1) Non-GAAP financial measures. See "Non-GAAP Financial Measures" for additional information.

(2) 2025 Financial Guidance as provided on August 7, 2025, excluded the impact of transaction-related costs. Also excluded any acquired IPR&D for unsigned deals to be incurred in any future period as it could not be reasonably forecasted.

(3) Includes estimated impact of shares repurchased in 2025 through and including November 5, 2025 and does not include the expected impact of additional share repurchases in 2025 after such date.

Ranges provided as of August 7, 2025, U.S. GAAP net cash provided by operating activities for 2025 was estimated to be between \$2.2 billion and \$2.5 billion, with a midpoint of approximately \$2.35 billion.

Certain Key Terms and Presentation Matters

New product sales, new product launches or new product revenues: Refers to revenue from new products launched in 2025 and the carryover impact of new products, including business development, launched within the last 12 months.

Operational change: Refers to constant currency percentage changes and is derived by translating amounts for the current period at prior year comparative period exchange rates and in doing so shows the percentage change from 2025 constant currency net sales, total revenues, adjusted EBITDA, and adjusted EPS to the corresponding amount in the prior year.

Divestiture-adjusted operational change: Refers to operational changes, further adjusted for the impact of the proportionate results from the divestitures that closed in 2024, from the 2024 period by excluding such net sales or revenues from those divested businesses from comparable prior periods. Also, for adjusted EBITDA and adjusted EPS, refers to operational changes, adjusted as outlined in the previous sentence and further adjusted for associated net other income.

SG&A and R&D TSA reimbursement and DSA reimbursement: Expenses related to TSA services provided for divested businesses are recorded in their respective functional line item. However, reimbursement of those expenses plus any mark-up is included in other expense (income), net. For comparability purposes, amounts related to the cost reimbursement were reclassified to adjusted SG&A and adjusted R&D during the first quarter of 2024, primarily related to the contribution of the biosimilars business to Biocon Biologics Limited ("Biocon Biologics") in November 2022. This reclassification had no impact on adjusted net earnings, adjusted EBITDA or adjusted EPS. Any TSA reimbursement and DSA reimbursement amounts related to the closed divestitures are not direct offsets to operational expense and have not been reclassified.

Closed divestitures or divestitures closed in 2024: Refers to the divestiture of the Company's rights to two women's healthcare products in the U.K. that closed in August 2024, the divestitures of the commercialization rights in the majority of the Upjohn Distributor markets that closed in 2024, the divestiture of the women's healthcare business that closed in March 2024, the divestiture of the API business in India that closed in June 2024, and the divestiture of the OTC business that closed in July 2024.

Indore Impact: Refers to the estimated negative financial impact on 2025 total revenues and earnings (loss) from operations versus the comparable 2024 periods as a result of supply disruptions and the FDA issued warning letter and import alert related to our oral finished dose manufacturing facility in Indore, India. For the three and nine months ended September 30, 2025, the estimated Indore Impact to total revenues was approximately \$100 million and \$400 million, respectively.

Transaction-related costs: Refers to the impact of any acquisition and divestiture-related transaction costs, including taxes.

Forward-Looking Statements

This press release contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about our 2025 financial guidance; we delivered another strong quarter by staying focused on our 2025 strategic priorities; our performance this quarter reflects the continued strength of our execution across markets; we are advancing our pipeline with key regulatory submissions and preparing for multiple potential launches, while preparing to take meaningful actions through our enterprise-wide strategic review to position Viatris for sustainable growth in 2026 and beyond; we remain confident in our strategy, our people, and our ability to deliver significant impact for patients and long-term value for shareholders; our third-quarter results again demonstrate strong operational execution and disciplined and balanced capital allocation; we are raising and narrowing our financial guidance ranges across certain metrics primarily driven by foreign exchange and share repurchases, and we remain on track to deliver on all of our 2025 financial commitments; based on the strength of recent Phase 3 clinical trial results in Japanese patients and the positive benefit-risk profile established globally, the Company is on track to file two JNDAs for pitolisant in Japan for two indications in the fourth quarter of 2025; one indication is for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy and the second is for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea syndrome; the Company anticipates approval of its low-dose estrogen weekly patch by mid-2026; the Company remains on track to deliver on its commitment of returning more than \$1 billion of capital to shareholders through dividends and share repurchases in 2025; from a business development perspective, the Company continues to pursue targeted, accretive business development opportunities that leverage its unique commercial and R&D infrastructure and strengthen its business in key markets; Viatris has made significant progress on its enterprise-wide strategic review since it announced the initiative in February and continues to perform a detailed analysis of the totality of its business; as part of the analysis to date, the Company has identified areas for potential operating efficiencies, including from: its commercial sales and marketing model and product mix, its R&D, medical and regulatory activities, its sourcing, manufacturing and supply chain, including inventory optimization; and, how its corporate functions provide support; while the review is still ongoing, the Company anticipates being able to deliver meaningful net cost savings over a multi-year period while also being able to reinvest a portion of the savings back into the business to fund growth opportunities; Viatris plans to hold an Investor Event in the first quarter of 2026 at which the Company plans to provide a strategic and financial outlook, an update on its pipeline and portfolio and details on its enterprise-wide strategic review; the goals or outlooks with respect to the Company's strategic initiatives and priorities, including but not limited to divestitures, acquisitions, strategic alliances, collaborations, or other potential transactions; the benefits and synergies of such divestitures, acquisitions, strategic alliances, collaborations, or other transactions, or restructuring programs; future opportunities for the Company and its products; and any other statements regarding the Company's future operations, financial or operating results, capital allocation, dividend policy and payments, share repurchases, debt ratio and covenants, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, commitments, confidence in future results, efforts to create, enhance or otherwise unlock value, and other expectations and targets for future periods. Forward-looking statements may often be identified by the use of words such as "will", "may", "could", "should", "would", "project", "believe", "anticipate", "expect", "plan", "estimate", "forecast", "potential", "pipeline", "intend", "continue", "target", "seek" and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possibility that the Company may not realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives and priorities (including divestitures, acquisitions, strategic alliances, collaborations, or other potential transactions) or accelerate its growth by building on the strength of its base business with an expanding portfolio of innovative, best-in-class, patent-protected assets; the possibility that the Company may be unable to achieve intended or expected benefits, goals, outlooks, synergies, growth opportunities and operating efficiencies in connection with divestitures, acquisitions, strategic alliances,

collaborations, or other transactions, or restructuring programs, within the expected timeframes or at all; the ongoing risks and uncertainties associated with our recent divestitures; goodwill or impairment charges or other losses; the Company's failure to achieve expected or targeted future financial and operating performance and results; the potential impact of natural or man-made disasters, public health outbreaks, epidemics, pandemics or social disruption in regions where we or our partners or suppliers operate; actions and decisions of healthcare and pharmaceutical regulators; changes in relevant laws, regulations and policies and/or the application or implementation thereof, including but not limited to tax, healthcare and pharmaceutical laws, regulations and policies globally; the ability to attract, motivate and retain key personnel; the Company's liquidity, capital resources and ability to obtain financing; any regulatory, legal or other impediments to the Company's ability to bring new products to market, including but not limited to "at-risk launches"; products in development that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; success of clinical trials and the Company's or its partners' ability to execute on new product opportunities and develop, manufacture and commercialize products; any changes in or difficulties with the Company's manufacturing facilities, including with respect to inspections, remediation and restructuring activities, supply chain or inventory or the ability to meet anticipated demand; the scope, timing and outcome of any ongoing legal proceedings, including government inquiries or investigations, and the impact of any such proceedings on the Company; any significant breach of data security or data privacy or disruptions to our IT systems; risks associated with having significant operations globally; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in the Company's or its partners' customer and supplier relationships and customer purchasing patterns, including customer loss and business disruption being greater than expected following an adverse regulatory action, acquisition or divestiture; the impacts of competition, including decreases in sales or revenues as a result of the loss of market exclusivity for certain products; changes in the economic and financial conditions of the Company or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential for adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with U.S. GAAP and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Viatriis, see the risks described in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as amended, Part II, Item 1A of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, Part II, Item 1A of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which is expected to be filed with the SEC on November 6, 2025, and our other filings with the SEC. You can access Viatriis' filings with the SEC through the SEC website at www.sec.gov or through our website, and Viatriis strongly encourages you to do so. Viatriis routinely posts information that may be important to investors on our website at investor.viatriis.com, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated into this press release or our filings with the SEC. Viatriis undertakes no obligation to update any statements herein for revisions or changes after the date of this press release other than as required by law.

Viatriis Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
<i>(In millions, except per share amounts)</i>				
Revenues:				
Net sales	\$ 3,747.5	\$ 3,738.0	\$ 10,559.7	\$ 11,177.4
Other revenues	12.4	13.2	36.6	33.8
Total revenues	3,759.9	3,751.2	10,596.3	11,211.2
Cost of sales	2,388.4	2,292.0	6,730.7	6,802.6
Gross profit	1,371.5	1,459.2	3,865.6	4,408.6
Operating expenses:				
Research and development	250.4	198.4	691.2	602.2
Acquired IPR&D	—	—	10.0	(1.7)
Selling, general and administrative ^(a)	886.6	1,003.4	2,763.4	3,057.9
Impairment of goodwill	—	—	2,936.8	321.0
Litigation settlements and other contingencies, net	55.7	31.5	(65.4)	239.3
Total operating expenses	1,192.7	1,233.3	6,336.0	4,218.7
Earnings (loss) from operations	178.8	225.9	(2,470.4)	189.9
Interest expense	119.6	145.6	351.7	429.8
Other expense (income), net	67.1	(10.2)	499.9	(143.2)
(Loss) earnings before income taxes	(7.9)	90.5	(3,322.0)	(96.7)
Income tax provision (benefit)	120.3	(4.3)	(147.2)	21.0
Net (loss) earnings	\$ (128.2)	\$ 94.8	\$ (3,174.8)	\$ (117.7)
(Loss) earnings per share attributable to Viatriis Inc. shareholders				
Basic	\$ (0.11)	\$ 0.08	\$ (2.70)	\$ (0.10)
Diluted	\$ (0.11)	\$ 0.08	\$ (2.70)	\$ (0.10)
Weighted average shares outstanding:				
Basic	1,164.6	1,193.5	1,176.7	1,193.3
Diluted	1,164.6	1,200.4	1,176.7	1,193.3

- (a) Certain reclassifications were made to conform the prior period consolidated financial statements to the current period presentation. Charges related to the impairment of goodwill, which were previously presented in Selling, General and Administrative, are now presented in Impairment of Goodwill in the condensed consolidated statements of operations.

Viatis Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)

(In millions)	September 30, December 31,	
	2025	2024
ASSETS		
Assets		
Current assets:		
Cash and cash equivalents	\$ 975.3	\$ 734.8
Accounts receivable, net	3,371.6	3,221.3
Inventories	4,111.4	3,854.1
Prepaid expenses and other current assets	1,493.1	1,710.5
Total current assets	9,951.4	9,520.7
Intangible assets, net	15,722.9	17,070.9
Goodwill	6,730.8	9,133.3
Other non-current assets	5,515.3	5,776.0
Total assets	\$ 37,920.4	\$ 41,500.9
LIABILITIES AND EQUITY		
Liabilities		
Current portion of long-term debt and other long-term obligations	\$ 1,951.9	\$ 8.3
Other current liabilities	5,412.2	5,771.1
Long-term debt	12,487.6	14,038.9
Other non-current liabilities	2,851.1	3,047.1
Total liabilities	22,702.8	22,865.4
Shareholders' equity	15,217.6	18,635.5
Total liabilities and equity	\$ 37,920.4	\$ 41,500.9

Viatis Inc. and Subsidiaries
Key Product Net Sales, on a Consolidated Basis
(Unaudited)

(In millions)	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
Select Key Global Products				
Lipitor ®	\$ 396.1	\$ 375.6	\$ 1,172.0	\$ 1,112.9
Norvasc ®	179.7	168.9	534.7	507.1
EpiPen® Auto-Injectors	157.2	123.2	390.7	318.9
Lyrica ®	126.5	129.9	367.2	368.4
Viagra ®	105.2	100.2	304.0	307.0
Creon ®	93.1	84.6	266.9	237.8
Celebrex ®	73.3	74.1	206.7	218.5
Effexor ®	67.2	66.3	189.6	188.4
Zoloft ®	66.8	60.6	188.1	177.5
Xalabrand	38.6	41.2	116.4	129.3
Select Key Segment Products				
Influvac ®	\$ 125.4	\$ 121.3	\$ 130.8	\$ 126.0
Yupelri ®	71.4	62.2	196.3	171.9
Amitiza ®	40.8	38.2	115.7	108.1
Xanax ®	34.2	38.6	100.4	108.5
Dymista ®	33.8	43.5	125.0	146.7

(a) The Company does not disclose net sales for any products considered competitively sensitive.

(b) Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.

(c) Amounts for the three and nine months ended September 30, 2025, include the impact of foreign currency translations compared to the prior year period.

Viatis Inc. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited)

Reconciliation of U.S. GAAP Net (Loss) Earnings to Adjusted Net Earnings and U.S. GAAP (Loss) Earnings Per Share to Adjusted EPS

Below is a reconciliation of U.S. GAAP net (loss) earnings and diluted (loss) earnings per share to adjusted net earnings and adjusted EPS for the three and nine months ended September 30, 2025, compared to the prior year period:

<i>(In millions, except per share amounts)</i>	Three Months Ended September 30,				Nine Months Ended September 30,			
	2025		2024		2025		2024	
U.S. GAAP net (loss) earnings and U.S. GAAP diluted (loss) earnings per share	\$ (128.2)	\$ (0.11)	\$ 94.8	\$ 0.08	\$ (3,174.8)	\$ (2.70)	\$ (117.7)	\$ (0.10)
Purchase accounting amortization (primarily included in cost of sales)	605.8		586.0		1,787.1		1,907.6	
Impairment of goodwill ^(a)	—		—		2,936.8		321.0	
Litigation settlements and other contingencies, net	55.7		31.5		(65.4)		239.3	
Interest expense (primarily amortization of premiums and discounts on long term debt)	(9.9)		0.4		(28.6)		(14.0)	
(Gain) loss on divestitures of businesses (included in other expense (income), net) ^(b)	(1.6)		107.4		79.1		295.8	
Acquisition and divestiture-related costs (primarily included in SG&A) ^(c)	40.0		98.2		134.4		290.8	
Restructuring costs ^(d)	17.2		105.4		136.7		146.1	
Share-based compensation expense	36.0		32.4		128.3		113.8	
Other special items included in:								
Cost of sales ^(e)	89.4		45.2		190.1		92.5	
Research and development expense	5.6		—		7.7		2.8	
Selling, general and administrative expense	18.0		15.5		65.7		43.1	
Other expense (income), net ^(f)	102.4		(43.9)		508.4		(322.1)	
Tax effect of the above items and other income tax related items ^(g)	(46.1)		(175.3)		(594.9)		(462.2)	
Adjusted net earnings and adjusted EPS	<u>\$ 784.3</u>	<u>\$ 0.67</u>	<u>\$ 897.6</u>	<u>\$ 0.75</u>	<u>\$ 2,110.6</u>	<u>\$ 1.78</u>	<u>\$ 2,536.8</u>	<u>\$ 2.11</u>
Weighted average diluted shares outstanding	<u>1,172.2</u>		<u>1,200.4</u>		<u>1,184.0</u>		<u>1,202.5</u>	

Significant items include the following:

- (a) For the nine months ended September 30, 2025, includes a goodwill impairment charge of \$2.9 billion as a result of the interim goodwill impairment test performed as of March 31, 2025.
- (b) For the nine months ended September 30, 2025, consists of pre-tax charges related to the divestitures primarily due to an increase in estimated transaction related costs, including the assumption of additional contractual obligations, as well as the impact of working capital and other transaction-related adjustments.
- (c) Acquisition and divestiture-related costs consist primarily of transaction costs including legal and consulting fees, and integration activities.
- (d) For the three and nine months ended September 30, 2025, includes approximately \$13.4 million and \$44.5 million, respectively, in cost of sales, and approximately \$3.7 million and \$90.0 million, respectively, in SG&A. For the nine months ended September 30, 2025, includes approximately \$2.2 million in R&D.
- (e) For the three and nine months ended September 30, 2025, includes incremental manufacturing variances at plants slated for sale or closure or undergoing remediation activities of approximately \$44.7 million and \$113.1 million, respectively.
- (f) For the three and nine months ended September 30, 2025, includes a loss of approximately \$100.0 million and \$499.8 million, respectively, as a result of remeasuring the compulsory convertible preferred shares in Biocon Biologics to fair value.
- (g) Adjusted for changes for uncertain tax positions.

Reconciliation of U.S. GAAP Net (Loss) Earnings to EBITDA and Adjusted EBITDA

Below is a reconciliation of U.S. GAAP net (loss) earnings to EBITDA and adjusted EBITDA for the three and nine months ended September 30, 2025,

compared to the prior year period:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
<i>(In millions)</i>				
U.S. GAAP net (loss) earnings	\$ (128.2)	\$ 94.8	\$ (3,174.8)	\$ (117.7)
Add / (deduct) adjustments:				
Income tax provision (benefit)	120.3	(4.3)	(147.2)	21.0
Interest expense ^(a)	119.6	145.6	351.7	429.8
Depreciation and amortization ^(b)	688.5	669.7	2,031.5	2,147.0
EBITDA	\$ 800.2	\$ 905.8	\$ (938.8)	\$ 2,480.1
Add / (deduct) adjustments:				
Share-based compensation expense	36.0	32.4	128.3	113.8
Litigation settlements and other contingencies, net	55.7	31.5	(65.4)	239.3
(Gain) loss on divestitures of businesses	(1.6)	107.4	79.1	295.8
Impairment of goodwill	—	—	2,936.8	321.0
Restructuring, acquisition and divestiture-related and other special items ^(c)	264.3	207.5	1,016.9	235.9
Adjusted EBITDA	\$ 1,154.6	\$ 1,284.6	\$ 3,156.9	\$ 3,685.9

(a) Includes amortization of premiums and discounts on long-term debt.

(b) Includes purchase accounting related amortization.

(c) See items detailed in the Reconciliation of U.S. GAAP Net (Loss) Earnings to Adjusted Net Earnings.

Summary of Total Revenues by Segment

(In millions, except %s)	Three Months Ended September 30,								
				2025 Currency Impact ⁽¹⁾	2025 Constant Currency Revenues	Constant Currency % Change ⁽²⁾	Closed Divestitures ⁽³⁾	2024 Adjusted Ex Divestitures ⁽⁴⁾	Divestiture- Adjusted Operational Change ⁽⁵⁾
	2025	2024	% Change						
Net sales									
Developed Markets	\$ 2,255.6	\$ 2,298.7	(2) %	\$ (76.0)	\$ 2,179.6	(5) %	\$ 11.1	\$ 2,287.6	(5) %
Greater China	615.2	561.8	10 %	(2.3)	612.9	9 %	—	561.8	9 %
JANZ	306.3	344.3	(11) %	4.3	310.6	(10) %	3.2	341.1	(9) %
Emerging Markets	570.4	533.2	7 %	(2.4)	568.0	7 %	4.3	528.9	7 %
Total net sales	3,747.5	3,738.0	— %	(76.4)	3,671.1	(2) %	\$ 18.6	\$ 3,719.4	(1) %
Other revenues ⁽⁶⁾	12.4	13.2	NM	(0.3)	12.1	NM	—	13.2	NM
Consolidated total revenues ⁽⁷⁾	\$ 3,759.9	\$ 3,751.2	— %	\$ (76.7)	\$ 3,683.2	(2) %	\$ 18.6	\$ 3,732.6	(1) %
(In millions, except %s)	Nine Months Ended September 30,								
				2025 Currency Impact ⁽¹⁾	2025 Constant Currency Revenues	Constant Currency % Change ⁽²⁾	Closed Divestitures ⁽³⁾	2024 Adjusted Ex Divestitures ⁽⁴⁾	Divestiture- Adjusted Operational Change ⁽⁵⁾
	2025	2024	% Change						
Net sales									
Developed Markets	\$ 6,266.6	\$ 6,783.3	(8) %	\$ (103.6)	\$ 6,163.0	(9) %	\$ 365.6	\$ 6,417.7	(4) %
Greater China	1,759.6	1,644.7	7 %	9.4	1,769.0	8 %	0.5	1,644.2	8 %
JANZ	888.1	1,011.7	(12) %	11.8	899.9	(11) %	24.0	987.7	(9) %
Emerging Markets	1,645.4	1,737.7	(5) %	29.6	1,675.0	(4) %	78.2	1,659.5	1 %
Total net sales	\$ 10,559.7	\$ 11,177.4	(6) %	\$ (52.8)	\$ 10,506.9	(6) %	\$ 468.3	\$ 10,709.1	(2) %
Other revenues ⁽⁶⁾	36.6	33.8	NM	(0.5)	36.1	NM	2.4	31.4	NM

Consolidated total revenues ⁽⁷⁾	\$	\$								
	10,596.3	11,211.2	(5) %	\$ (53.3)	\$ 10,543.0	(6) %	\$ 470.7	\$ 10,740.5	(2) %	

(1) Currency impact is shown as unfavorable (favorable).

(2) The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period exchange rates, and in doing so shows the percentage change from 2025 constant currency net sales or revenues to the corresponding amount in the prior year.

(3) Represents proportionate net sales relating to divestitures that closed during 2024 in the relevant period.

(4) Represents U.S. GAAP net sales minus proportionate net sales relating to divestitures that closed during 2024 for the relevant period.

(5) See "Certain Key Terms and Presentation Matters" in this release for more information.

(6) For the three months ended September 30, 2025, other revenues in Developed Markets, JANZ, and Emerging Markets were approximately \$10.0 million, \$1.0 million, and \$1.4 million, respectively. For the nine months ended September 30, 2025, other revenues in Developed Markets, JANZ, and Emerging Markets were approximately \$27.2 million, \$3.0 million, and \$6.4 million, respectively.

(7) Amounts exclude intersegment revenue which eliminates on a consolidated basis.

Reconciliation of Statements of Operations Line Items

(Unaudited)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
(In millions, except %s)	2025	2024	2025	2024
U.S. GAAP cost of sales	\$ 2,388.4	\$ 2,292.0	\$ 6,730.7	\$ 6,802.6
Deduct:				
Purchase accounting amortization and other related items	(605.8)	(586.2)	(1,787.1)	(1,907.6)
Acquisition and divestiture-related costs	(23.6)	(18.8)	(62.2)	(42.1)
Restructuring costs	(13.4)	(82.7)	(44.5)	(98.3)
Share-based compensation expense	(0.7)	(0.8)	(2.9)	(2.5)
Other special items, including restructuring related costs	(89.4)	(45.2)	(190.1)	(92.5)
Adjusted cost of sales	\$ 1,655.5	\$ 1,558.3	\$ 4,643.9	\$ 4,659.6
Adjusted gross profit ^(a)	\$ 2,104.4	\$ 2,192.9	\$ 5,952.4	\$ 6,551.6
Adjusted gross margin ^(a)	56 %	58 %	56 %	58 %

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
(In millions, except %s)	2025	2024	2025	2024
U.S. GAAP R&D	\$ 250.4	\$ 198.4	\$ 691.2	\$ 602.2
Deduct:				
Acquisition and divestiture-related costs	(5.7)	(1.6)	(9.0)	(9.3)
Restructuring costs	—	(0.9)	(2.2)	(1.9)
Share-based compensation expense	(1.4)	(1.7)	(5.9)	(5.4)
SG&A and R&DTSA reimbursement and DSA reimbursement ^(b)	—	—	—	(1.7)
Other special items	(5.6)	—	(7.7)	(2.8)
Adjusted R&D	\$ 237.7	\$ 194.2	\$ 666.4	\$ 581.1
Adjusted R&D as % of total revenues	6 %	5 %	6 %	5 %

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
(In millions, except %s)	2025	2024	2025	2024
U.S. GAAP SG&A ^(c)	\$ 886.6	\$ 1,003.4	\$ 2,763.4	\$ 3,057.9

Deduct:

Acquisition and divestiture-related costs	(10.6)	(77.9)	(63.1)	(239.3)
Restructuring costs	(3.7)	(21.8)	(90.0)	(45.9)
Purchase accounting amortization and other related items	—	0.2	—	—
Share-based compensation expense	(33.8)	(29.8)	(119.4)	(105.9)
SG&A and R&DTSA reimbursement and DSA reimbursement ^(b)	—	—	—	(5.7)
Other special items and reclassifications	(18.0)	(15.5)	(65.7)	(43.1)
Adjusted SG&A	\$ 820.5	\$ 858.6	\$ 2,425.2	\$ 2,618.0

Adjusted SG&A as % of total revenues

22 %	23 %	23 %	23 %
------	------	------	------

(In millions)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
U.S. GAAP total operating expenses	\$ 1,192.7	\$ 1,233.3	\$ 6,336.0	\$ 4,218.7
Add / (Deduct):				
Litigation settlements and other contingencies, net	(55.7)	(31.5)	65.4	(239.3)
R&D adjustments	(12.7)	(4.2)	(24.8)	(21.1)
SG&A adjustments ^(c)	(66.1)	(144.8)	(338.2)	(439.9)
Impairment of goodwill adjustments	—	—	(2,936.8)	(321.0)
Adjusted total operating expenses	\$ 1,058.2	\$ 1,052.8	\$ 3,101.6	\$ 3,197.4
Adjusted earnings from operations ^(d)	\$ 1,046.2	\$ 1,140.1	\$ 2,850.8	\$ 3,354.2

(In millions)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
U.S. GAAP interest expense	\$ 119.6	\$ 145.6	\$ 351.7	\$ 429.8
Add / (Deduct):				
Accretion of contingent consideration liability	(1.1)	(11.4)	(3.5)	(22.6)
Amortization of premiums and discounts on long-term debt	11.7	12.0	34.1	39.3
Other special items	(0.7)	(0.9)	(2.0)	(2.7)
Adjusted interest expense	\$ 129.5	\$ 145.3	\$ 380.3	\$ 443.8

(In millions)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
U.S. GAAP other expense (income), net	\$ 67.1	\$ (10.2)	\$ 499.9	\$ (143.2)
Add / (Deduct):				
Fair value adjustments on non-marketable equity investments	(100.0)	39.4	(499.8)	335.1
SG&A and R&DTSA reimbursement and DSA reimbursement ^(b)	—	—	—	7.4
Gain (loss) on divestitures of businesses	1.6	(107.4)	(79.1)	(295.8)
Other items	(2.6)	4.5	(8.7)	(12.9)
Adjusted other income, net	\$ (33.9)	\$ (73.7)	\$ (87.7)	\$ (109.4)

(In millions, except %s)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
U.S. GAAP (loss) earnings before income taxes	\$ (7.9)	\$ 90.5	\$ (3,322.0)	\$ (96.7)
Total pre-tax non-GAAP adjustments	958.5	978.0	5,880.3	3,116.7
Adjusted earnings before income taxes	\$ 950.6	\$ 1,068.5	\$ 2,558.3	\$ 3,020.0
U.S. GAAP income tax provision (benefit)	\$ 120.3	\$ (4.3)	\$ (147.2)	\$ 21.0
Adjusted tax expense	46.1	175.3	594.9	462.2

Adjusted income tax provision	\$	166.4	\$	171.0	\$	447.7	\$	483.2
-------------------------------	----	-------	----	-------	----	-------	----	-------

Adjusted effective tax rate		17.5 %		16.0 %		17.5 %		16.0 %
-----------------------------	--	--------	--	--------	--	--------	--	--------

- (a) U.S. GAAP gross profit is calculated as total revenues less U.S. GAAP cost of sales. U.S. GAAP gross margin is calculated as U.S. GAAP gross profit divided by total revenues. Adjusted gross profit is calculated as total revenues less adjusted cost of sales. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.
- (b) Refer to "Certain Key Terms and Presentation Matters" section in this release for more information on reclassifications related to TSA and DSA reimbursements.
- (c) Certain reclassifications were made to conform the prior period consolidated financial statements to the current period presentation. Charges related to the impairment of goodwill, which were previously presented in Selling, General and Administrative, are now presented in Impairment of Goodwill in the condensed consolidated statements of operations.
- (d) U.S. GAAP earnings from operations is calculated as U.S. GAAP gross profit less U.S. GAAP total operating expenses. Adjusted earnings from operations is calculated as adjusted gross profit less adjusted total operating expenses.

Reconciliation of Estimated 2025 U.S. GAAP Net Cash Provided by Operating Activities to Free Cash Flow as of November 6, 2025

(Unaudited)

A reconciliation of the estimated 2025 U.S. GAAP Net Cash provided by Operating Activities to Free Cash Flow is presented below:

(In millions)

Estimated U.S. GAAP Net Cash provided by Operating Activities ^(a)	\$2,200 - \$2,450
--	-------------------

Less: Capital Expenditures	<u>\$(300) - \$(350)</u>
----------------------------	--------------------------

Free Cash Flow ^(a)	\$1,850 - \$2,150
-------------------------------	-------------------

(a) Excludes the impact of any transaction-related costs.

Reconciliation of Estimated 2025 U.S. GAAP Net Cash Provided by Operating Activities to Free Cash Flow as of August 7, 2025

(Unaudited)

A reconciliation of the estimated 2025 U.S. GAAP Net Cash provided by Operating Activities to Free Cash Flow is presented below:

(In millions)

Estimated U.S. GAAP Net Cash provided by Operating Activities ^(a)	\$2,200 - \$2,500
--	-------------------

Less: Capital Expenditures	<u>\$(300) - \$(400)</u>
----------------------------	--------------------------

Free Cash Flow ^(a)	\$1,800 - \$2,200
-------------------------------	-------------------

(a) Excluded the impact of any transaction-related costs.



VIATRIS

VIATRIS Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

- Delivered Total Revenues in Line with Expectations, Reflecting Strong Execution of its Global Business
- Advanced Late Stage Pipeline Progress Including NDA Submissions for Late-Stage Oncology Biologics
- Acquired Assets/Pharmas Including Rights to Products in Japan and South Korea and Certain Other Markets in the Asia-Pacific Region
- Achieved More Than \$200 Million of Capital in Share Repurchases, Including \$100 Million in Share Repurchases
- Reaffirmed 2025 Financial Guidance Ranges for Total Revenues, Adjusted EBITDA and Adjusted EPS

Reaffirmation – November 6, 2025 – **VIATRIS Inc.** (NYSE:VTRS) today reported strong third quarter 2025 financial results and updated its 2025 financial guidance.

Executive Commentary

"We delivered another strong quarter by staying focused on our 2025 strategic priorities," said **Joseph A. Bazzoli**, Chief Executive Officer, Viatris. "The performance this quarter reflects the continued strength of our commercial success metrics. We are advancing our pipeline with key regulatory submissions and preparing for multiple potential launches, and continuing to make meaningful progress through our strategic debt strategy, which is further driving the sustainable growth in 2025 and beyond. We remain confident in our strategy, our pipeline, and our ability to deliver significant value to patients and long-term value to shareholders."

"Our third quarter results again demonstrate strong operational execution and disciplined and sustained capital allocation," said **Joseph Bazzoli**, Viatris President and CEO. "Viatris has made more than \$200 million of capital in repurchases year-to-date, including \$100 million in share repurchases. We are raising and reconfirming our financial guidance ranges across certain metrics primarily driven by strategic debt program and share repurchases, and we remain on track to deliver on all of our 2025 financial commitments."



View original content to download multimedia:<https://www.prnewswire.com/news-releases/viatris-reports-third-quarter-2025-results-and-updates-2025-financial-guidance-302606363.html>

SOURCE Viatris Inc.

Media: 1.724.514.1968, Communications@viatris.com; Jennifer Mauer, Jennifer.Mauer@viatris.com; Matt Klein, Matthew.Klein@viatris.com;
Investors: 1.724.514.1813, InvestorRelations@viatris.com; Bill Szablewski, William.Szablewski@viatris.com